HDL cholesterol and protective factors in atherosclerosis

Circulation

Volumn 109, Issue 23 SUPPL., 2004, Pages

  Assmann, Gerd ^a   Gotto Jr , Antonio M ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Atherosclerosis; Cardiovascular diseases; Cholesterol; High density lipoprotein (HDL); Lipoproteins; Risk factors

Indexed keywords

APOLIPOPROTEIN A1; ATORVASTATIN; BEZAFIBRATE; CHOLESTEROL ESTER TRANSFER PROTEIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; SIMVASTATIN; STATINE DERIVATIVE;

ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG TARGETING; ENDOTHELIUM CELL; FLUSHING; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; HYPERURICEMIA; ISCHEMIC HEART DISEASE; LIVER TOXICITY; MUSCLE DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK FACTOR;

ADULT; AGED; ANIMALS; ANTILIPEMIC AGENTS; ARTERIOSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CHOLESTEROL; CHOLESTEROL, HDL; DISEASE SUSCEPTIBILITY; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERLIPIDEMIAS; LIVER; MALE; MEMBRANE LIPIDS; MICE; MICE, TRANSGENIC; MIDDLE AGED; OXIDATION-REDUCTION; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 2942750054     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Gordon DH, Rifkind BM. High-density lipoprotein: the clinical implications of recent studies. N Engl J Med. 1989;321:1311-1316.
2. Barter P. CETP and atherosclerosis. Arterioscler Thromb Vasc Biol. 2000;20:2029-2031.
3. von Eckardstein A, Nofer JR, Assmann G. High density lipoproteins and arteriosclerosis: role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 2001;21:13-27.
4. von Eckardstein A, Nofer JR, Assmann G. Acceleration of reverse cholesterol transport. Curr Opin Cardiol. 2000;15:348-354.
5. Brooks-Wilson A, Marcil M, Clee SM, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet. 1999;22:336-345.
6. Bodzioch M, Orso E, Klucken J, et al. The gene encoding ATP-binding cassette transporter I is mutated in Tangier disease. Nat Genet. 1999;22:347-351.
7. Rust S, Rosier M, Funke H, et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet. 1999;22:352-355.
8. Bungert S, Molday LL, Molday RS. Membrane topology of the ATP binding cassette transporter ABCR and its relationship to ABC1 and related ABCA transporters: identification of N-linked glycosylation sites. J Biol Chem. 2001;276:23539-23546.
9. Oram JF, Lawn RM, Garvin MR, et al. ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages. J Biol Chem. 2000;275:34508-34511.
10. Wang N, Silver DL, Costet P, et al. Specific binding of apo A-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1. J Biol Chem. 2000;275:33053-33058.
11. Wang N, Silver DL, Thiele C, et al. ATP-binding cassette transporter AI (ABCA1) functions as a cholesterol efflux regulatory protein. J Biol Chem. 2001;276:23742-23747.
12. Chambenoit O, Hamon Y, Marguet D, et al. Specific docking of apolipoprotein A-1 at the cell surface requires a functional ABCA1 transporter. J Biol Chem. 2001;276:9955-9960.
13. Drobnik W, Borsukova H, Bottcher A, et al. Apo AI/ABCA1-dependent and HDL3-mediated lipid efflux from compositionally distinct cholesterol-based microdomains. Traffic. 2002;3:268-278.
14. Neufeld EB, Remaley AT, Demosky SJ, et al. Cellular localization and trafficking of the human ABCA1 transporter. J Biol Chem. 2001;276:27584-27590.
15. Tsukamoto K, Hirano K, Tsujii K, et al. ATP-binding cassette transporter-I induces rearrangement of actin cytoskeletons possibly through Cdc42/N-WASP. Biochem Biophys Res Commun. 2001;287:757-765.
16. Lin G. Insights of high-density lipoprotein apolipoprotein-mediated lipid efflux from cells. Biochem Biophys Res Commun. 2002;291:727-731.
17. von Eckardstein A, Langer C, Engel T, et al. ATP binding cassette transporter ABCA1 modulates the secretion of apolipoprotein E from human monocyte-derived macrophages. FASEB J. 2001;15:1555-1561.
18. McNeish J, Aiello RJ, Guyot D, et al. High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1. Proc Natl Acad Sci USA. 2000;97:4245-4250.
19. Aiello RJ, Brees D, Bourassa PA, et al. Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages. Arterioscler Thromb Vasc Biol. 2002;22:630-637.
20. Vaisman BL, Lambert G, Amar M, et al. ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice. J Clin Invest. 2001;108:303-309.
21. Joyce CW, Amar MJ, Lambert G, et al. The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice. Proc Natl Acad Sci USA. 2002;99:407-412.
22. Haghpassand M, Bourassa PA, Francone OL, et al. Monocyte/macrophage expression of ABCA1 has minimal contribution to plasma HDL levels. J Clin Invest. 2001;108:1315-1320.
23. van Eck M, Bos IS, Kaminski WE, et al. Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues. Proc Natl Acad Sci U S A. 2002;99:6298-6303.
24. Spieker LE, Sudano I, Hurlimann D, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation. 2002;105:1399-1402.
25. Cockerill GW, Huehns TY, Weerasinghe A, et al. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation. 2001;103:108-112.
26. Dimayuga P, Zhu J, Oguchi S, et al. Reconstituted HDL containing human apolipoprotein A-1 reduces VCAM-1 expression and neointima formation following periadventitial cuff-induced carotid injury in apoE null mice. Biochem Biophys Res Commun. 1999;264:465-468.
27. Yuhanna IS, Zhu Y, Cox BE, et al, High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med. 2001;7:853-857.
28. Li XA, Titlow WB, Jackson BA, et al. High density lipoprotein binding to scavenger receptor, Class B, type I activates endothelial nitric-oxide synthase in a ceramide-dependent manner. J Biol Chem. 2002;277:11058-11063.
29. Cockerill GW, McDonald MC, Mota-Filipe H, et al. High density lipoproteins reduce organ injury and organ dysfunction in a rat model of hemorrhagic shock. FASEB J. 2001;15:1941-1952.
30. Nofer JR, Levkau B, Wolinska I, et al. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem. 2001;276:34480-34485.
31. Kimura T, Sato K, Kuwabara A, et al. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J Biol Chem. 2001;276:31780-31785.
32. Nofer JR, van der Giet M, Tölle M, et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3: role of HDL-associated lysophospholipids. J Clin Invest. 2004;113:569-581.
33. Cullen P, Schulte H, Assmann G. Smoking, lipoproteins and coronary heart disease risk: data from the Münster Heart Study (PROCAM). Eur Heart J. 1998;19:1632-1641.
34. Nofer JR, Kehrel B, Fobker M, et al. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis. 2002;161:1-16.
35. Navab M, Hama SY, Anantharamaiah GM, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res. 2000;41:1495-1508.
36. Navab M, Berliner JA, Subbanagounder G, et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol. 2001;21:481-488.
37. Assmann G, Nofer J-R. Atheroprotective effects of high-density lipoproteins. Annu Rev Med. 2003;54:321-341.
38. Shih DM, Gu L, Xia YR, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 1998;394:284-287.
39. Shih DM, Xia YR, Wang XP, et al. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem. 2000;275:17527-17535.
40. Oda MN, Bielicki JK, Ho TT, et al. Paraoxonase 1 overexpression in mice and its effect on high-density lipoproteins. Biochem Biophys Res Commun. 2002;290:921-927.
41. Theilmeier G, de Geest B, van Veldhoven PP, et al. HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/- mice. FASEB J. 2000;14:2032-2039.
42. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. Circulation. 2002;106:3143-3421.
43. Gotto AM Jr. Low high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report. Circulation. 2001;103:2213-2218.
44. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol. 1992;70:733-737.
45. Despres JP, Lemieux I, Dagenais GR, et al. HDL-cholesterol as a marker of coronary heart disease risk: the Québec Cardiovascular Study. Atherosclerosis. 2000;153:263-272.
46. Schaefer EJ, Lamon-Fava S, Ordovas JM, et al. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-1 levels in the Framingham Offspring Study. J Lipid Res. 1994;35:871-882.
47. Austin MA, Rodriquez BL, McKnight B, et al. Low-density lipoprotein particle size, triglycerides, and high-density lipoprotein cholesterol as risk factors for coronary heart disease in older Japanese-American men. Am J Cardiol. 2000;86:412-416.
48. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989;79:8-15.
49. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-1245.
50. Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 1988;260:641-651.
51. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410-418.
52. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: a randomized controlled trial. JAMA. 2001;285:1585-1591.
53. BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) Study. Circulation. 2000;102:21-27.
54. Rizos E, Mikhailidis DP. Are high-density lipoprotein and triglyceride levels important in secondary prevention? Impressions from the BIP and VA-HIT trials. Int J Cardiol. 2002;82:199-207.
55. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003;92:152-160.
56. Gotto AM Jr, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 2000;101:477-484.
57. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
58. Ballantyne CM, Herd JA, Ferlic LL, et al. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation. 1999;99:736-743.
59. Hunninghake DB, McGovern ME, Koren M, et al. A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin. Clin Cardiol. 2003;26:112-118.
60. Niaspan (niacin extended-release tablets) [prescribing information]. Miami, Fl: Kos Pharmaceuticals, Inc. Available at: http://www.niaspan. com/templates/hcp.asp?class=2&page=. Accessed November 21, 2003.
61. Pasternak RC, Smith SC, Bairey-Merz CN, et al. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. J Am Coll Cardiol. 2002;40:567-572.
62. Fruchart JC. Peroxisome proliferator-activated receptor-α activation and high-density lipoprotein metabolism. Am J Cardiol. 2001;88(suppl): 24N-29N.
63. Guerin M, Lassel TS, Le Goff W, et al. Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol. 2000;20:189-197.
64. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292-2300.
65. Boden WE, Pearson TA. Raising low levels of high-density lipoprotein cholesterol is an important target of therapy. Am J Cardiol. 2000;85:645-649.